Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Phase I/II Multicenter Clinical Trial of NECVAX-NEO1 as add-on to First-line Neoadjuvant Anti-PD-1 Monoclonal Antibody Therapy in Patients With Triple-negative Breast Cancer

Next Previous
Trial Profile

An Open-label, Phase I/II Multicenter Clinical Trial of NECVAX-NEO1 as add-on to First-line Neoadjuvant Anti-PD-1 Monoclonal Antibody Therapy in Patients With Triple-negative Breast Cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NECVAX NEO1 (Primary) ; Carboplatin; Cyclophosphamide; Doxorubicin; Epirubicin
  • Indications Advanced breast cancer; Triple negative breast cancer
  • Focus Adverse reactions
  • Sponsors NEC Bio

Most Recent Events

  • 20 Feb 2026 Planned number of patients changed from 8 to 12.
  • 20 Feb 2026 Planned End Date changed from 31 Dec 2028 to 31 Dec 2029.
  • 20 Feb 2026 Planned primary completion date changed from 31 Dec 2025 to 31 Dec 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top